Latest News & Updates

Breaking News

  • 11 hours ago

  • Simantini Singh Deo

AstraZeneca Achieves 43% UPCR Reduction with Ultomiris in Phase III IgA Nephropathy Trial
Breaking News
Eli Lilly Achieves Significant Fat Loss Outcomes in Oral GLP-1 Phase 3 Menopause Subgroup Analysis

Simantini Singh Deo

Other trending news you may like to read

AstraZeneca Achieves 43% UPCR Reduction with Ultomiris in Phase III IgA Nephropathy Trial

Ultomiris hits 43.4% UPCR reduction at 34 weeks in Phase III IgA nephropathy trial, signalling a potential new indication filing with FDA and EMA.

Simantini Singh Deo

Pharma Now

Eli Lilly Achieves Significant Fat Loss Outcomes in Oral GLP-1 Phase 3 Menopause Subgroup Analysis

Eli Lilly's oral GLP-1 candidate shows fat loss across menopause stages in Phase 3 ATTAIN trials, raising scale-up and formulation questions.

Simantini Singh Deo

Pharma Now

Lupin Signs Deal with Laboratorios ERN to Launch Luforbec Inhaler Across Spain

Lupin partners with Laboratorios ERN to commercialise Luforbec in Spain, combining inhaler manufacturing depth with local distribution reach.

Simantini Singh Deo

Pharma Now

SPI Pharma Acquires Elementis Pharma, Expanding European Excipient Manufacturing Footprint in Germany

SPI Pharma completes acquisition of Elementis Pharma, adding German GMP manufacturing capacity and specialty excipients for digestive health formulations.

Simantini Singh Deo

Pharma Now